FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304080647> ?p ?o ?g. }

• W4304080647 endingPage "5078" @default.
• W4304080647 startingPage "5066" @default.
• W4304080647 abstract "Abstract Purpose: Sensitivity to endocrine therapy (ET) is critical for the clinical benefit from the combination of palbociclib plus ET in hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer. Bazedoxifene is a third-generation selective estrogen receptor (ER) modulator and selective ER degrader with activity in preclinical models of endocrine-resistant breast cancer, including models harboring ESR1 mutations. Clinical trials in healthy women showed that bazedoxifene is well tolerated. Patients and Methods: We conducted a phase Ib/II study of bazedoxifene plus palbociclib in patients with HR+/HER2− advanced breast cancer who progressed on prior ET (N = 36; NCT02448771). Results: The study met its primary endpoint, with a clinical benefit rate of 33.3%, and the safety profile was consistent with what has previously been seen with palbociclib monotherapy. The median progression-free survival (PFS) was 3.6 months [95% confidence interval (CI), 2.0–7.2]. An activating PIK3CA mutation at baseline was associated with a shorter PFS (HR = 4.4; 95% CI, 1.5–13; P = 0.0026), but activating ESR1 mutations did not impact the PFS. Longitudinal plasma circulating tumor DNA whole-exome sequencing (WES; N = 68 plasma samples) provided an overview of the tumor heterogeneity and the subclonal genetic evolution, and identified actionable mutations acquired during treatment. Conclusions: The combination of palbociclib and bazedoxifene has clinical efficacy and an acceptable safety profile in a heavily pretreated patient population with advanced HR+/HER2− breast cancer. These results merit continued investigation of bazedoxifene in breast cancer." @default.
• W4304080647 created "2022-10-10" @default.
• W4304080647 creator A5001392592 @default.
• W4304080647 creator A5003120045 @default.
• W4304080647 creator A5017140112 @default.
• W4304080647 creator A5027545866 @default.
• W4304080647 creator A5030263464 @default.
• W4304080647 creator A5032785430 @default.
• W4304080647 creator A5041089077 @default.
• W4304080647 creator A5051532432 @default.
• W4304080647 creator A5051714606 @default.
• W4304080647 creator A5053368670 @default.
• W4304080647 creator A5055378234 @default.
• W4304080647 creator A5056686039 @default.
• W4304080647 creator A5058208718 @default.
• W4304080647 creator A5058306766 @default.
• W4304080647 creator A5061172218 @default.
• W4304080647 creator A5062055452 @default.
• W4304080647 creator A5062515397 @default.
• W4304080647 creator A5062762227 @default.
• W4304080647 creator A5069056507 @default.
• W4304080647 creator A5070245248 @default.
• W4304080647 creator A5079430523 @default.
• W4304080647 date "2022-10-10" @default.
• W4304080647 modified "2023-10-03" @default.
• W4304080647 title "Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor–Positive Breast Cancer" @default.
• W4304080647 cites W1978981428 @default.
• W4304080647 cites W1986798894 @default.
• W4304080647 cites W1997006452 @default.
• W4304080647 cites W2005866113 @default.
• W4304080647 cites W2019607817 @default.
• W4304080647 cites W2025647698 @default.
• W4304080647 cites W2034294845 @default.
• W4304080647 cites W2037341816 @default.
• W4304080647 cites W2038189029 @default.
• W4304080647 cites W2044702943 @default.
• W4304080647 cites W2067328809 @default.
• W4304080647 cites W2067873262 @default.
• W4304080647 cites W2071433338 @default.
• W4304080647 cites W2096283457 @default.
• W4304080647 cites W2099493846 @default.
• W4304080647 cites W2100826058 @default.
• W4304080647 cites W2111324624 @default.
• W4304080647 cites W2114843025 @default.
• W4304080647 cites W2127041368 @default.
• W4304080647 cites W2129036353 @default.
• W4304080647 cites W2135944809 @default.
• W4304080647 cites W2138601221 @default.
• W4304080647 cites W2141137976 @default.
• W4304080647 cites W2144957807 @default.
• W4304080647 cites W2148345265 @default.
• W4304080647 cites W2149441684 @default.
• W4304080647 cites W2152035198 @default.
• W4304080647 cites W2162627731 @default.
• W4304080647 cites W2170490448 @default.
• W4304080647 cites W2257497411 @default.
• W4304080647 cites W2279216355 @default.
• W4304080647 cites W2309969893 @default.
• W4304080647 cites W2343368549 @default.
• W4304080647 cites W2415372857 @default.
• W4304080647 cites W2527720111 @default.
• W4304080647 cites W2560367415 @default.
• W4304080647 cites W2614443510 @default.
• W4304080647 cites W2741790413 @default.
• W4304080647 cites W2765435739 @default.
• W4304080647 cites W2773831165 @default.
• W4304080647 cites W2788279409 @default.
• W4304080647 cites W2791176983 @default.
• W4304080647 cites W2808757951 @default.
• W4304080647 cites W2809032787 @default.
• W4304080647 cites W2867868648 @default.
• W4304080647 cites W2884903585 @default.
• W4304080647 cites W2892043300 @default.
• W4304080647 cites W2904240523 @default.
• W4304080647 cites W2918928681 @default.
• W4304080647 cites W2925017918 @default.
• W4304080647 cites W2945564879 @default.
• W4304080647 cites W2946317931 @default.
• W4304080647 cites W2949512680 @default.
• W4304080647 cites W3000078203 @default.
• W4304080647 cites W3002154893 @default.
• W4304080647 cites W3009578620 @default.
• W4304080647 cites W3015634062 @default.
• W4304080647 cites W3024684302 @default.
• W4304080647 cites W3029661147 @default.
• W4304080647 cites W3031721927 @default.
• W4304080647 cites W3056495303 @default.
• W4304080647 cites W3128758614 @default.
• W4304080647 cites W3176308859 @default.
• W4304080647 cites W4206711305 @default.
• W4304080647 cites W4226537594 @default.
• W4304080647 cites W4280490473 @default.
• W4304080647 cites W4280516872 @default.
• W4304080647 doi "https://doi.org/10.1158/1078-0432.ccr-22-2305" @default.
• W4304080647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36215125" @default.
• W4304080647 hasPublicationYear "2022" @default.
• W4304080647 type Work @default.
• W4304080647 citedByCount "2" @default.

• next